

Special Issue

New Advances of Brain Metastasis in Oncology

Message from the Guest Editor

This Special Issue provides a comprehensive framework for understanding brain metastasis, encompassing its sequential steps, underlying molecular mechanisms, and emerging therapeutic strategies. Recent advances in oncology have significantly enhanced the understanding and management of brain metastases. Progress in molecular profiling has identified tumor-specific driver proteins and critical signaling pathways that facilitate cancer cell traversal across the blood–brain barrier, enabling improved risk stratification and the development of targeted therapies. Targeted agents and next-generation tyrosine kinase inhibitors with enhanced central nervous system penetration have demonstrated promising intracranial efficacy across multiple cancer types. Collectively, these developments are transforming brain metastasis management toward personalized, multidisciplinary care, thereby improving survival and quality of life. The purpose of this Special Issue is to present the new insights into the development of brain metastases, focusing on protein-based biomarkers, underlying molecular mechanisms, and advances in therapeutic strategies.

Guest Editor

Dr. Shailendra Kumar Maurya

Department of Biochemistry and Molecular Biology, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA

Deadline for manuscript submissions

5 December 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/266194

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)